Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
(Cilofexor + firsocostat) by Gilead Sciences for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
(Cilofexor + firsocostat) is under clinical development by Gilead Sciences and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH)....